Official websites use .gov
A
.gov
website belongs to an official government organization in the
United States.
Secure .gov websites use HTTPS
A
lock
(
) or
https://
means you’ve safely connected to the .gov website. Share sensitive
information only on official, secure websites.
PubMed ID:
35059607
Public Release Type:
Journal
Publication Year: 2021
DOI:
https://doi.org/10.1016/j.isci.2021.103697
Authors:
Hopp Katharina, Catenacci Victoria A., Dwivedi Nidhi, Kline Timothy L., Wang Wei, You Zhiying, Nguyen Dustin T., Bing Kristen, Poudyal Bhavya, Johnson Ginger C., Jackman Matthew R., Miller Marsha, Steele Cortney N., Serkova Natalie J., MacLean Paul S., Nemenoff Raphael A., Gitomer Berenice, Chonchol Michel, Nowak Kristen L.
Request IDs:
20959
,
22080
Studies:
The HALT Progression of Polycystic Kidney Disease (HALT-PKD)
Progression of autosomal dominant polycystic kidney disease (ADPKD) is modified by metabolic defects and obesity. Indeed, reduced food intake slows cyst growth in preclinical rodent studies. Here, we demonstrate the feasibility of daily caloric restriction (DCR) and intermittent fasting (IMF) in a cohort of overweight or obese patients with ADPKD. Clinically significant weight loss occurred with both DCR and IMF; however, weight loss was greater and adherence and tolerability were better with DCR. Further, slowed kidney growth correlated with body weight and visceral adiposity loss independent of dietary regimen. Similarly, we compared the therapeutic efficacy of DCR, IMF, and time restricted feeding (TRF) using an orthologous ADPKD mouse model. Only ADPKD animals on DCR lost significant weight and showed slowed cyst growth compared to ad libitum, IMF, or TRF feeding. Collectively, this supports therapeutic feasibility of caloric restriction in ADPKD, with potential efficacy benefits driven by weight loss.
